NCT03852251View on ClinicalTrials.gov

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

March 25, 2024

Study Completion Date

March 25, 2024

Conditions
Gastric AdenocarcinomaAdvanced Solid TumorsGastroesophageal Junction Adenocarcinoma
Interventions
BIOLOGICAL

AK104

Subjects will receive AK104 by intravenous administration.

DRUG

Oxaliplatin

Subjects will receive AK104 in combination with oxaliplatin and capecitabine.

DRUG

Capecitabine

Subjects will receive AK104 in combination with oxaliplatin and capecitabine.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Akeso

INDUSTRY